Scribe Therapeutics Inc. (NASDAQ:SCTX – Free Report) – Equities research analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of Scribe Therapeutics in a report released on Thursday, September 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.42) per share for the quarter, up from their previous estimate of ($1.02). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Scribe Therapeutics’ current full-year earnings is ($3.68) per share. HC Wainwright also issued estimates for Scribe Therapeutics’ Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($3.68) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($2.52) EPS.
Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last posted its earnings results on Wednesday, September 2nd. The company reported ($3.84) earnings per share for the quarter, beating the consensus estimate of ($6.20) by $2.36. The firm had revenue of $1.92 million for the quarter, compared to analysts’ expectations of $3.10 million.
Read Our Latest Research Report on Scribe Therapeutics
Scribe Therapeutics Stock Up 9.3%
NASDAQ:SCTX opened at $31.34 on Monday. Scribe Therapeutics has a 52 week low of $17.31 and a 52 week high of $39.60.
Insider Activity at Scribe Therapeutics
In related news, CFO David Parrot purchased 2,666 shares of Scribe Therapeutics stock in a transaction that occurred on Thursday, July 23rd. The stock was purchased at an average cost of $15.00 per share, with a total value of $39,990.00. Following the completion of the transaction, the chief financial officer directly owned 1,333 shares in the company, valued at approximately $19,995. The trade was a -200.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carl Gordon bought 1,000,000 shares of Scribe Therapeutics stock in a transaction dated Monday, July 27th. The stock was purchased at an average cost of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the acquisition, the director directly owned 1,348,825 shares in the company, valued at approximately $20,232,375. The trade was a 286.68% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 3,727,237 shares of company stock valued at $56,291,746 over the last quarter.
About Scribe Therapeutics
Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.
Further Reading
- Five stocks we like better than Scribe Therapeutics
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
